alexis theron

Dr. alexis theron

Assistance Publique des Hopitaux de Marseille, Marseille 05, France
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in International Journal of Cardiology
Verified
Journal Article
Closed access
LBLaurent Bonello
Laurent Bonello
OCOlivier Com
Olivier Com
OAOmar Ait-Moktar
Omar Ait-Moktar
ATalexis theron
alexis theron
PMPierre-Julien Moro
Pierre-Julien Moro
FPFranck Paganelli
Franck Paganelli

1 March 2014 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
CTChristophe Tribouilloy
Christophe Tribouilloy
DRDan Rusinaru
Dan Rusinaru
FGFrancesco Grigioni
Francesco Grigioni
HMHector I. Michelena
Hector I. Michelena
JVJean-Louis Vanoverschelde
Jean-Louis Vanoverschelde
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano
Background—: Ejection fraction (EF) as a marker of left ventricular (LV) dysfunction and the appropriate thresholds for diagnosing severe or mild/moderate LV dysfunction in mitral regurgitation are doubted and poorly followed in clinical practice. We aimed at assessing the role of EF in a large registry of organic mitral regurgitation to objectively establish thresholds for various degrees of LV dysfunction and to analyze whether mitral surgery remains beneficial in those subsets of patients. Methods and Results—: We investigated the relation between EF and mortality in 1875 patients with mitral regurgitation due to flail leaflets in sinus rhythm (65±13 years; median EF, 66% [60%–71%]) enrolled in the Mitral Regurgitation International Database (MIDA) registry. With EF <60%, mortality after diagnosis increased precipitously under medical management (adjusted hazard ratio [HR], 1.59 [1.19–2.12]) and during the entire follow-up (adjusted HR, 1.51 [1.22–1.87]). Severe LV dysfunction, if defined by EF <30%, would affect a minuscule number of patients (0.3%). Conversely, EF 60%. Above 60%, no EF threshold further determined survival. The benefit of surgery remained considerable in the groups with EF <45% (adjusted HR, 0.28 [0.17–0.56]) and with EF of 45% to 60% (adjusted HR, 0.34 [0.21–0.64]). Conclusions—: EF is valuable in defining presence and severity of LV dysfunction in organic mitral regurgitation. Patients with EF 60%, with EF dropping <60%, mortality increases precipitously and prompt surgical referral is critical to outcome.

16 May 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JAJean-Fançois Avierinos
Jean-Fançois Avierinos
CTChristophe Tribouilloy
Christophe Tribouilloy
FBFrancesca Bursi
Francesca Bursi
FGFrancesco Grigioni
Francesco Grigioni
JVJean-Louis Vanoverschelde
Jean-Louis Vanoverschelde
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano
Presentation, outcome, and management of females with degenerative mitral regurgitation (DMR) are undefined. We analysed sex-specific baseline clinical and echocardiographic characteristics at referral for DMR due to flail leaflets and subsequent management and outcomes. In the Mitral Regurgitation International Database (MIDA) international registry, females were compared with males regarding presentation at referral, management, and outcome (survival/heart failure), under medical treatment, post-operatively, and encompassing all follow-up. At referral, females (n = 650) vs. males (n = 1660) were older with more severe symptoms and higher MIDA score. Smaller cavity diameters belied higher cardiac dimension indexed to body surface area. Under conservative management, excess mortality vs. expected was observed in males [standardized mortality ratio (SMR) 1.45 (1.27–1.65), P < .001] but was higher in females [SMR 2.00 (1.67–2.38), P < .001]. Female sex was independently associated with mortality [adjusted hazard ratio (HR) 1.29 (1.04–1.61), P = .02], cardiovascular mortality [adjusted HR 1.58 (1.14–2.18), P = .007], and heart failure [adjusted HR 1.36 (1.02–1.81), P = .04] under medical management. Females vs. males were less offered surgical correction (72% vs. 80%, P < .001); however, surgical outcome, adjusted for more severe presentation in females, was similar (P ≥ .09). Ultimately, overall outcome throughout follow-up was worse in females who displayed persistent excess mortality vs. expected [SMR 1.31 (1.16–1.47), P < .001], whereas males enjoyed normal life expectancy restoration [SMR 0.92 (0.85–0.99), P = .036]. Females with severe DMR were referred to tertiary centers at a more advanced stage, incurred higher mortality and morbidity under conservative management, and were offered surgery less and later after referral. Ultimately, these sex-related differences yielded persistent excess mortality despite surgery in females with DMR, while males enjoyed restoration of life expectancy, warranting imperative re-evaluation of sex-specific DMR management. Comparison of severe degenerative mitral regurgitation presentation, management, and outcome between males and females. Females vs. males are less referred to tertiary care centers, at a later stage of severe degenerative mitral regurgitation (left), display more severe outcome under medical management (top middle), and are less referred to mitral repair with later indications (bottom middle) but have similar post-operative outcome when operated. They ultimately incur excess overall mortality under medical and surgical management combined, whereas normal life expectancy is restored in males (right). Black solid line denotes observed survival, dotted lines 95% confidence interval, and straight line expected survival. MIDA, Mitral Regurgitation International Database; SMR, standardized mortality ratio.

17 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PDPierre Deharo
Pierre Deharo
LLLionel Leroux
Lionel Leroux
ATalexis theron
alexis theron
JFJerome Ferrara
Jerome Ferrara
AVAntoine Vaillier
Antoine Vaillier
TCThomas Cuisset
Thomas Cuisset
Background: Transcatheter aortic valve implantation (TAVI) is the preferred treatment for symptomatic severe aortic stenosis (AS) in a majority of patients across all surgical risks. Patients and methods: Paravalvular leak (PVL) and patient–prosthesis mismatch (PPM) are two frequent complications of TAVI. Therefore, based on the large France-TAVI registry, we planned to report the incidence of both complications following TAVI, evaluate their respective risk factors, and study their respective impacts on long-term clinical outcomes, including mortality. Results: We identified 47,494 patients in the database who underwent a TAVI in France between 1 January 2010 and 31 December 2019. Within this population, 17,742 patients had information regarding PPM status (5138 with moderate-to-severe PPM, 29.0%) and 20,878 had information regarding PVL (4056 with PVL ≥ 2, 19.4%). After adjustment, the risk factors for PVL ≥ 2 were a lower body mass index (BMI), a high baseline mean aortic gradient, a higher body surface area, a lower ejection fraction, a smaller diameter of TAVI, and a self-expandable TAVI device, while for moderate-to-severe PPM we identified a younger age, a lower BMI, a larger body surface area, a low aortic annulus area, a low ejection fraction, and a smaller diameter TAVI device (OR 0.85; 95% CI, 0.83–0.86) as predictors. At 6.5 years, PVL ≥ 2 was an independent predictor of mortality and was associated with higher mortality risk. PPM was not associated with increased risk of mortality. Conclusions: Our analysis from the France-TAVI registry showed that both moderate-to-severe PPM and PVL ≥ 2 continue to be frequently observed after the TAVI procedure. Different risk factors, mostly related to the patient’s anatomy and TAVI device selection, for both complications have been identified. Only PVL ≥ 2 was associated with higher mortality during follow-up.

24 October 2014 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
GOGaelle Odelin
Gaelle Odelin
EFEmilie FAURE
Emilie FAURE
FKFrank Kober
Frank Kober
CMCorinne Maurel-Zaffran
Corinne Maurel-Zaffran
ATalexis theron
alexis theron
Stéphane ZaffranStéphane Zaffran
Stéphane Zaffran
Aims Heart valve maturation is achieved by the organization of extracellular matrix (ECM) and the distribution of valvular interstitial cells. However, the factors that regulate matrix components required for valvular structure and function are unknown. Based on the discovery of its specific expression in cardiac valves, we aimed to uncover the role of Krox20 ( Egr-2 ) during valve development and disease. Methods and results Using series of mouse genetic tools, we demonstrated that loss of function of Krox20 caused significant hyperplasia of the semilunar valves, while atrioventricular valves appeared normal. This defect was associated with an increase in valvular interstitial cell number and ECM volume. Echo Doppler analysis revealed that adult mutant mice had aortic insufficiency. Defective aortic valves (AoVs) in Krox20−/− mice had features of human AoV disease, including excess of proteoglycan deposition and reduction of collagen fibres. Furthermore, examination of diseased human AoVs revealed decreased expression of KROX20 . To identify downstream targets of Krox20, we examined expression of fibrillar collagens in the AoV leaflets at different stages in the mouse. We found significant down-regulation of Col1a1 , Col1a2 , and Col3a1 in the semilunar valves of Krox20 mutant mice. Utilizing in vitro and in vivo experiments, we demonstrated that Col1a1 and Col3a1 are direct targets of Krox20 activation in interstitial cells of the AoV. Conclusion This study identifies a previously unknown function of Krox20 during heart valve development. These results indicate that Krox20-mediated activation of fibrillar Col1a1 and Col3a1 genes is crucial to avoid postnatal degeneration of the AoV leaflets.

18 November 2015 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
ATalexis theron
alexis theron
VGVlad Gariboldi
Vlad Gariboldi
DGDominique Grisoli
Dominique Grisoli
NJNicolas Jaussaud
Nicolas Jaussaud
PMPierre Morera
Pierre Morera
FCFrederic Collart
Frederic Collart